Annelies Wilder-Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7354158/publications.pdf

Version: 2024-02-01

281 papers

14,688 citations

23879 60 h-index 103 g-index

288 all docs

288 docs citations

times ranked

288

17777 citing authors

#	Article	IF	CITATIONS
1	What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?. Lancet Infectious Diseases, The, 2022, 22, 152-153.	4.6	46
2	The silent and dangerous inequity around access to COVID-19 testing: A call to action. EClinicalMedicine, 2022, 43, 101230.	3.2	33
3	Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. Lancet Infectious Diseases, The, 2022, 22, 657-667.	4.6	68
4	Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. The Lancet Global Health, 2022, 10, e326-e328.	2.9	62
5	Emerging evidence on heterologous COVID-19 vaccine schedulesâ€"To mix or not to mix?. Lancet Infectious Diseases, The, 2022, 22, 438-440.	4.6	27
6	Does the World Still Need New Covid-19 Vaccines?. New England Journal of Medicine, 2022, 386, 2140-2142.	13.9	36
7	Evaluation of Zika rapid tests as aids for clinical diagnosis and epidemic preparedness. EClinicalMedicine, 2022, 49, 101478.	3.2	5
8	Impact of BMI on COVID-19 vaccine effectiveness. Lancet Diabetes and Endocrinology, the, 2022, 10, 551-552.	5.5	4
9	Curbing the COVID-19 pandemic with facility-based isolation of mild cases: a mathematical modeling study. Journal of Travel Medicine, 2021, 28, .	1.4	24
10	Optimising dengue pre-vaccination screening. Lancet Infectious Diseases, The, 2021, 21, 442-444.	4.6	12
11	Modelling the test, trace and quarantine strategy to control the COVID-19 epidemic in the state of São Paulo, Brazil. Infectious Disease Modelling, 2021, 6, 46-55.	1.2	21
12	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet, The, 2021, 397, 562-564.	6.3	105
13	Correcting COVID-19 vaccine misinformation. EClinicalMedicine, 2021, 33, 100780.	3.2	63
14	SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review. BMJ Open, 2021, 11, e045425.	0.8	43
15	Novel vaccine safety issues and areas that would benefit from further research. BMJ Global Health, 2021, 6, e003814.	2.0	4
16	COVID-19 vaccine impact in Israel and a way out of the pandemic. Lancet, The, 2021, 397, 1783-1785.	6.3	68
17	Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine, 2021, 36, 100925.	3.2	11
18	Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine, 2021, 36, 100911.	3.2	7

#	Article	IF	Citations
19	Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine, 2021, 39, 4013-4024.	1.7	110
20	The expanding geographic range of dengue in Australia. Medical Journal of Australia, 2021, 215, 171-172.	0.8	6
21	COVID-19 transmission and the safety of air travel during the pandemic: a scoping review. Current Opinion in Infectious Diseases, 2021, 34, 415-422.	1.3	13
22	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. PLoS Medicine, 2021, 18, e1003772.	3.9	7
23	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine, 2021, 39, 101053.	3.2	45
24	Effectiveness of an Inactivated SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 385, 946-948.	13.9	51
25	What Is the Impact of Lockdowns on Dengue?. Current Infectious Disease Reports, 2021, 23, 2.	1.3	34
26	Differential Household Attack Rates Mirror the Ability to Control Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2021, 72, e1166-e1167.	2.9	1
27	Dengue during the COVID-19 pandemic. Journal of Travel Medicine, 2021, 28, .	1.4	10
28	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. Global Health Action, 2021, 14, 2008139.	0.7	5
29	Preparedness for emerging epidemic threats: a Lancet Infectious Diseases Commission. Lancet Infectious Diseases, The, 2020, 20, 17-19.	4.6	50
30	Recombination of B- and T-cell epitope-rich loci from Aedes- and Culex-borne flaviviruses shapes Zika virus epidemiology. Antiviral Research, 2020, 174, 104676.	1.9	11
31	Dengue vaccine development: status and future. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2020, 63, 40-44.	7.2	46
32	In-flight transmission of SARS-CoV-2: a review of the attack rates and available data on the efficacy of face masks. Journal of Travel Medicine, 2020, 27, .	1.4	83
33	Dengue vaccine development by the year 2020: challenges and prospects. Current Opinion in Virology, 2020, 43, 71-78.	2.6	48
34	Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. Npj Vaccines, 2020, 5, 54.	2.9	41
35	Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential. Lancet Infectious Diseases, The, 2020, 20, e268-e273.	4.6	33
36	Modelling lockdown and exit strategies for COVID-19 in Singapore. The Lancet Regional Health - Western Pacific, 2020, 1, 100004.	1.3	57

#	Article	IF	Citations
37	COVID-19 healthcare demand and mortality in Sweden in response to non-pharmaceutical mitigation and suppression scenarios. International Journal of Epidemiology, 2020, 49, 1443-1453.	0.9	46
38	Strategies at points of entry to reduce importation risk of COVID-19 cases and reopen travel. Journal of Travel Medicine, 2020, 27 , .	1.4	69
39	Serum chymase levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients. Scientific Reports, 2020, 10, 11856.	1.6	19
40	A reverse transcription loop-mediated isothermal amplification for broad coverage detection of Asian and African Zika virus lineages. BMC Infectious Diseases, 2020, 20, 947.	1.3	2
41	Institutional versus home isolation to curb the COVID-19 outbreak – Authors' reply. Lancet, The, 2020, 396, 1632-1633.	6.3	10
42	Public health emergencies of international concern: a historic overview. Journal of Travel Medicine, 2020, 27, .	1.4	116
43	Editorial overview: The challenge to defeat dengue. Current Opinion in Virology, 2020, 43, iii-v.	2.6	3
44	Institutional, not home-based, isolation could contain the COVID-19 outbreak. Lancet, The, 2020, 395, 1541-1542.	6.3	99
45	Successful smallpox eradication: what can we learn to control COVID-19?. Journal of Travel Medicine, 2020, 27, .	1.4	10
46	Lockdown to contain COVID-19 is a window of opportunity to prevent the second wave. Journal of Travel Medicine, 2020, 27, .	1.4	29
47	Modelling the effect of a dengue vaccine on reducing the evolution of resistance against antibiotic due to misuse in dengue cases. Theoretical Biology and Medical Modelling, 2020, 17, 7.	2.1	5
48	Two complementary model-based methods for calculating the risk of international spreading of a novel virus from the outbreak epicentre. The case of COVID-19. Epidemiology and Infection, 2020, 148, e109.	1.0	13
49	The Lancet Commission on dengue and other Aedes-transmitted viral diseases. Lancet, The, 2020, 395, 1890-1891.	6.3	12
50	The global community needs to swiftly ramp up the response to contain COVID-19. Lancet, The, 2020, 395, 1109-1110.	6.3	138
51	Evaluation of a tetravalent dengue vaccine by serostatus and serotype. Lancet, The, 2020, 395, 1402-1404.	6.3	5
52	Estimation of the COVID-19 burden in Egypt through exported case detection. Lancet Infectious Diseases, The, 2020, 20, 894.	4.6	36
53	Epidemic preparedness in urban settings: new challenges and opportunities. Lancet Infectious Diseases, The, 2020, 20, 527-529.	4.6	90
54	Can we contain the COVID-19 outbreak with the same measures as for SARS?. Lancet Infectious Diseases, The, 2020, 20, e102-e107.	4.6	693

#	Article	IF	Citations
55	Estimation of COVID-19 burden in Egypt – Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 897-898.	4.6	1
56	Zika among international travellers presenting to GeoSentinel sites, 2012–2019: implications for clinical practice. Journal of Travel Medicine, 2020, 27, .	1.4	18
57	End of year editorial: hot topics in travel medicine. Journal of Travel Medicine, 2020, 27, .	1.4	4
58	Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia. BMJ Open, 2020, 10, e035307.	0.8	10
59	Postnatal symptomatic Zika virus infections in children and adolescents: A systematic review. PLoS Neglected Tropical Diseases, 2020, 14, e0008612.	1.3	12
60	Preventing Dengue Epidemics during the COVID-19 Pandemic. American Journal of Tropical Medicine and Hygiene, 2020, 103, 570-571.	0.6	66
61	COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Swiss Medical Weekly, 2020, 150, w20225.	0.8	367
62	Evaluation of intensified dengue control measures with interrupted time series analysis in the Panadura Medical Officer of Health division in Sri Lanka: a case study and cost-effectiveness analysis. Lancet Planetary Health, The, 2019, 3, e211-e218.	5.1	23
63	Severe dengue in travellers: pathogenesis, risk and clinical management. Journal of Travel Medicine, 2019, 26, .	1.4	86
64	Modelling the importation risk of measles during the Hajj. Lancet Infectious Diseases, The, 2019, 19, 806.	4.6	4
65	Estimating the dengue burden in India. The Lancet Global Health, 2019, 7, e988-e989.	2.9	26
66	Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure. PLoS Neglected Tropical Diseases, 2019, 13, e0007482.	1.3	23
67	ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas. Global Health Action, 2019, 12, 1666566.	0.7	13
68	Modelling an optimum vaccination strategy against ZIKA virus for outbreak use. Epidemiology and Infection, 2019, 147, e196.	1.0	5
69	Yellow Fever in Travelers. Current Infectious Disease Reports, 2019, 21, 42.	1.3	5
70	Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015–2016 Zika virus epidemic: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2019, 13, e0007622.	1.3	36
71	Dengue. Lancet, The, 2019, 393, 350-363.	6.3	420
72	Understanding the relation between Zika virus infection during pregnancy and adverse fetal, infant and child outcomes: a protocol for a systematic review and individual participant data meta-analysis of longitudinal studies of pregnant women and their infants and children. BMJ Open, 2019, 9, e026092.	0.8	36

#	Article	IF	Citations
7 3	Dengue: An Expanding Neglected Tropical Disease. Neglected Tropical Diseases, 2019, , 65-84.	0.4	3
74	Improving clinical management of patients with severe yellow fever. Lancet Infectious Diseases, The, 2019, 19, 678-679.	4.6	3
75	Application of a targeted-enrichment methodology for full-genome sequencing of Dengue 1-4, Chikungunya and Zika viruses directly from patient samples. PLoS Neglected Tropical Diseases, 2019, 13, e0007184.	1.3	15
76	Yellow fever: is Asia prepared for an epidemic?. Lancet Infectious Diseases, The, 2019, 19, 241-242.	4.6	12
77	Mass Gatherings. , 2019, , 383-386.		2
78	Long-Term Protection After Fractional-Dose Yellow Fever Vaccination. Annals of Internal Medicine, 2019, 171, 145.	2.0	3
79	Misguided approach to dengue vaccine risk. Science, 2019, 366, 1082-1083.	6.0	3
80	Unprecedented rise in dengue outbreaks in Bangladesh. Lancet Infectious Diseases, The, 2019, 19, 1287.	4.6	45
81	Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerging Microbes and Infections, 2019, 8, 1734-1746.	3.0	18
82	The first licensed dengue vaccine. Current Opinion in Infectious Diseases, 2019, 32, 394-400.	1.3	13
83	Vaccine-attributable severe dengue in the Philippines. Lancet, The, 2019, 394, 2151-2152.	6.3	23
84	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infectious Diseases, The, 2019, 19, e31-e38.	4.6	120
85	Can dengue virus be sexually transmitted?. Journal of Travel Medicine, 2019, 26, .	1.4	14
86	Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine, 2019, 37, 863-868.	1.7	60
87	Semiannual Versus Annual Influenza Vaccination in Older Adults in the Tropics: An Observer-blind, Active-comparator–controlled, Randomized Superiority Trial. Clinical Infectious Diseases, 2019, 69, 121-129.	2.9	14
88	Dengue virus–elicited tryptase induces endothelial permeability and shock. Journal of Clinical Investigation, 2019, 129, 4180-4193.	3.9	60
89	Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. Wellcome Open Research, 2019, 4, 165.	0.9	23
90	A Prospective Study on the Impact and Out-of-Pocket Costs of Dengue Illness in International Travelers. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1525-1533.	0.6	12

#	Article	IF	CITATIONS
91	Zika virus infection in the returning traveller: what every neurologist should know. Practical Neurology, 2018, 18, 271-277.	0.5	25
92	Dengue virus not detected in human semen. Journal of Travel Medicine, 2018, 25, .	1.4	17
93	Asymptomatic Prenatal Zika Virus Infection and Congenital Zika Syndrome. Open Forum Infectious Diseases, 2018, 5, ofy073.	0.4	32
94	Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. Journal of Infectious Diseases, 2018, 217, 731-741.	1.9	105
95	Estimating the probability of dengue virus introduction and secondary autochthonous cases in Europe. Scientific Reports, 2018, 8, 4629.	1.6	44
96	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine, 2018, 36, 3411-3417.	1.7	52
97	Influenza on cruise ships. Journal of Travel Medicine, 2018, 25, .	1.4	7
98	Novel tools for the surveillance and control of dengue: findings by the DengueTools research consortium. Global Health Action, 2018, 11, 1549930.	0.7	10
99	Sentinel Surveillance in Travel Medicine: 20 Years of GeoSentinel Publications (1999–2018). Journal of Travel Medicine, 2018, 25, .	1.4	33
100	Projecting the end of the Zika virus epidemic in Latin America: a modelling analysis. BMC Medicine, 2018, 16, 180.	2.3	53
101	Reply to â€~Timing of administration of dengue vaccine in travellers with a recent confirmed dengue infection'. Journal of Travel Medicine, 2018, 25, .	1.4	1
102	Risk of Dengue in Travelers: Implications for Dengue Vaccination. Current Infectious Disease Reports, 2018, 20, 50.	1.3	17
103	The risk of urban yellow fever resurgence in <i>Aedes</i> Infested American cities. Epidemiology and Infection, 2018, 146, 1219-1225.	1.0	17
104	Dengue vaccine: reliably determining previous exposure. The Lancet Global Health, 2018, 6, e830-e831.	2.9	27
105	Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMC Medicine, 2018, 16, 84.	2.3	70
106	Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers. Journal of Travel Medicine, 2018, 25, .	1.4	33
107	Fractional-Dose Yellow Fever Vaccination — Advancing the Evidence Base. New England Journal of Medicine, 2018, 379, 603-605.	13.9	43
108	Zika in travellers 1947–2017: a systematic review. Journal of Travel Medicine, 2018, 25, .	1.4	63

#	Article	IF	CITATIONS
109	Leptospirosis among Returned Travelers: A GeoSentinel Site Survey and Multicenter Analysis—1997–2016. American Journal of Tropical Medicine and Hygiene, 2018, 99, 127-135.	0.6	12
110	Responding to the threat of urban yellow fever outbreaks. Lancet Infectious Diseases, The, 2017, 17, 248-250.	4.6	32
111	An update on Zika vaccine developments. Expert Review of Vaccines, 2017, 16, 781-787.	2.0	46
112	Moving forward with Takeda's live chimeric tetravalent dengue vaccine. Lancet Infectious Diseases, The, 2017, 17, 566-568.	4.6	4
113	Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine, 2017, 35, 212-221.	1.7	78
114	Epidemic arboviral diseases: priorities for research and public health. Lancet Infectious Diseases, The, 2017, 17, e101-e106.	4.6	394
115	Travel-Associated Zika Virus Disease Acquired in the Americas Through February 2016. Annals of Internal Medicine, 2017, 166, 99.	2.0	67
116	Yellow fever vaccination: estimating coverage. Lancet Infectious Diseases, The, 2017, 17, 1109-1111.	4.6	15
117	Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. Journal of Infectious Diseases, 2017, 216, 1112-1121.	1.9	48
118	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	1.7	81
119	Importation of yellow fever into China: assessing travel patterns. Journal of Travel Medicine, 2017, 24,	1.4	64
120	Closing the gap in travel medicine. Journal of Travel Medicine, 2017, 24, .	1.4	16
121	Utilization of HIV testing services among pregnant mothers in low income primary care settings in northern Ethiopia: a cross sectional study. BMC Pregnancy and Childbirth, 2017, 17, 199.	0.9	28
122	The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial. Trials, 2017, 18, 67.	0.7	4
123	Travel medicine perspectives of select travel medicine experts practicing in the Asia-Pacific region. Journal of Travel Medicine, 2017, 24, .	1.4	16
124	Analysis of Dengue Serotype 4 in Sri Lanka during the 2012–2013 Dengue Epidemic. American Journal of Tropical Medicine and Hygiene, 2017, 97, 130-136.	0.6	12
125	Mitigating Diseases Transmitted by Aedes Mosquitoes: A Cluster-Randomised Trial of Permethrin-Impregnated School Uniforms. PLoS Neglected Tropical Diseases, 2017, 11, e0005197.	1.3	30
126	Household costs of hospitalized dengue illness in semi-rural Thailand. PLoS Neglected Tropical Diseases, 2017, 11, e0005961.	1.3	20

#	Article	IF	Citations
127	Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. Eurosurveillance, 2017, 22, .	3.9	46
128	Laboratory-Enhanced Dengue Sentinel Surveillance in Colombo District, Sri Lanka: 2012-2014. PLoS Neglected Tropical Diseases, 2016, 10, e0004477.	1.3	26
129	Personal Protection of Permethrin-Treated Clothing against Aedes aegypti, the Vector of Dengue and Zika Virus, in the Laboratory. PLoS ONE, 2016, 11, e0152805.	1.1	48
130	A Spatial Hierarchical Analysis of the Temporal Influences of the El Ni $ ilde{A}\pm$ o-Southern Oscillation and Weather on Dengue in Kalutara District, Sri Lanka. International Journal of Environmental Research and Public Health, 2016, 13, 1087.	1.2	36
131	Early detection of Zika virus infection among travellers from areas of ongoing transmission in China: Table 1. Journal of Travel Medicine, 2016, 23, taw047.	1.4	24
132	Estimated Zika virus importations to Europe by travellers from Brazil. Global Health Action, 2016, 9, 31669.	0.7	54
133	Internet-based media coverage on dengue in Sri Lanka between 2007 and 2015. Global Health Action, 2016, 9, 31620.	0.7	6
134	Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. International Journal of Infectious Diseases, 2016, 49, 18-29.	1.5	31
135	Utilising additional sources of information on microcephaly. Lancet, The, 2016, 387, 940-941.	6.3	2
136	Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate. Vaccine, 2016, 34, 2397-2401.	1.7	18
137	Modeling Importations and Exportations of Infectious Diseases via Travelers. Bulletin of Mathematical Biology, 2016, 78, 185-209.	0.9	46
138	Estimated global exportations of Zika virus infections via travellers from Brazil from 2014 to 2015:. Journal of Travel Medicine, 2016, 23, taw059.	1.4	30
139	The olympically mismeasured risk of Zika virus in Rio de Janeiro – Authors' reply. Lancet, The, 2016, 388, 658-659.	6.3	5
140	Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine. Journal of Infectious Diseases, 2016, 214, 1796-1799.	1.9	55
141	Assessing Seasonal Risks for the Introduction and Mosquito-borne Spread of Zika Virus in Europe. EBioMedicine, 2016, 9, 250-256.	2.7	91
142	Characteristics of and factors associated with dengue vector breeding sites in the City of Colombo, Sri Lanka. Pathogens and Global Health, 2016, 110, 79-86.	1.0	29
143	Is Zika a substantial risk for visitors to the Rio de Janeiro Olympic Games?. Lancet, The, 2016, 388, 25.	6.3	30
144	Climate Change and Aedes Vectors: 21st Century Projections for Dengue Transmission in Europe. EBioMedicine, 2016, 7, 267-277.	2.7	140

#	Article	IF	CITATIONS
145	The risk of dengue for non-immune foreign visitors to the 2016 summer olympic games in Rio de Janeiro, Brazil. BMC Infectious Diseases, 2016, 16, 186.	1.3	31
146	Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Review of Vaccines, 2016, 15, 437-441.	2.0	17
147	Dissecting Japan's Dengue Outbreak in 2014. American Journal of Tropical Medicine and Hygiene, 2016, 94, 409-412.	0.6	53
148	Points for Consideration for dengue vaccine introduction – recommendations by the Dengue Vaccine Initiative. Expert Review of Vaccines, 2016, 15, 529-538.	2.0	10
149	Edging closer towards the goal of a dengue vaccine. Expert Review of Vaccines, 2016, 15, 433-435.	2.0	10
150	The elusive global burden of dengue. Lancet Infectious Diseases, The, 2016, 16, 629-631.	4.6	32
151	Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and na $ ilde{A}$ ve vaccinees. Human Vaccines and Immunotherapeutics, 2016, 12, 1265-1273.	1.4	20
152	Carriage of Neisseria meningitidis in the Hajj and Umrah mass gatherings. International Journal of Infectious Diseases, 2016, 47, 65-70.	1.5	32
153	Markers of dengue severity: a systematic review of cytokines and chemokines. Journal of General Virology, 2016, 97, 3103-3119.	1.3	50
154	Costs of Dengue Control Activities and Hospitalizations in the Public Health Sector during an Epidemic Year in Urban Sri Lanka. PLoS Neglected Tropical Diseases, 2016, 10, e0004466.	1.3	41
155	Spatial Variations in Dengue Transmission in Schools in Thailand. PLoS ONE, 2016, 11, e0161895.	1.1	18
156	Estimating Air Travel–Associated Importations of Dengue Virus Into Italy. Journal of Travel Medicine, 2015, 22, 186-193.	1.4	38
157	Road traffic injuries in northern Laos: trends and risk factors of an underreported public health problem. Tropical Medicine and International Health, 2015, 20, 1578-1587.	1.0	15
158	Increasing Dengue Incidence in Singapore over the Past 40 Years: Population Growth, Climate and Mobility. PLoS ONE, 2015, 10, e0136286.	1.1	117
159	Dengue Vaccines for Travelers: Has the Time Come?. Journal of Travel Medicine, 2015, 22, 200-202.	1.4	4
160	Early Detection of Dengue Virus by Use of Reverse Transcription-Recombinase Polymerase Amplification. Journal of Clinical Microbiology, 2015, 53, 830-837.	1.8	87
161	Virus-specific T lymphocytes home to the skin during natural dengue infection. Science Translational Medicine, 2015, 7, 278ra35.	5.8	83
162	Reviewing Dengue: Still a Neglected Tropical Disease?. PLoS Neglected Tropical Diseases, 2015, 9, e0003632.	1.3	70

#	Article	IF	CITATIONS
163	A Simple and Powerful Method for the Estimation of Intervention Effects on Serological Endpoints Using Paired Interval-Censored Data. Journal of Biopharmaceutical Statistics, 2015, 25, 124-136.	0.4	3
164	Dengue vaccines at a crossroad. Science, 2015, 350, 626-627.	6.0	28
165	Potential for international spread of wild poliovirus via travelers. BMC Medicine, 2015, 13, 133.	2.3	44
166	Importation Index of Dengue to Determine the Most Probable Origin of Importation. Journal of Travel Medicine, 2015, 22, 72-72.	1.4	15
167	Permethrin-Treated Clothing as Protection against the Dengue Vector, Aedes aegypti: Extent and Duration of Protection. PLoS Neglected Tropical Diseases, 2015, 9, e0004109.	1.3	33
168	Use of Insecticide-Treated School Uniforms for Prevention of Dengue in Schoolchildren: A Cost-Effectiveness Analysis. PLoS ONE, 2014, 9, e108017.	1.1	15
169	Risk of symptomatic dengue for foreign visitors to the 2014 FIFA World Cup in Brazil. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 394-397.	0.8	27
170	Attack rates of dengue fever in Swedish travellers. Scandinavian Journal of Infectious Diseases, 2014, 46, 412-417.	1.5	22
171	Modeling tools for dengue risk mapping - a systematic review. International Journal of Health Geographics, 2014, 13, 50.	1.2	97
172	Effects of India's new polio policy on travellers. Lancet, The, 2014, 383, 1632.	6.3	7
173	Dengue outlook for the World Cup in Brazil. Lancet Infectious Diseases, The, 2014, 14, 552-553.	4.6	13
174	Dengue vaccines: dawning at last?. Lancet, The, 2014, 384, 1327-1329.	6.3	34
175	Severe Neutropenia in Dengue Patients: Prevalence and Significance. American Journal of Tropical Medicine and Hygiene, 2014, 90, 984-987.	0.6	29
176	The Role of International Travel in the Spread ofÂMethicillinâ€Resistant Staphylococcus aureus. Journal of Travel Medicine, 2014, 21, 272-281.	1.4	50
177	Dengue: Challenges for Policy Makers and Vaccine Developers. Current Infectious Disease Reports, 2014, 16, 404.	1.3	23
178	The 2012 dengue outbreak in Madeira: exploring the origins. Eurosurveillance, 2014, 19, 20718.	3.9	80
179	Acceptability of impregnated school uniforms for dengue control in Thailand: a mixed methods approach. Global Health Action, 2014, 7, 24887.	0.7	12
180	The potential for a controlled human infection platform in Singapore. Singapore Medical Journal, 2014, 55, 456-461.	0.3	15

#	Article	IF	CITATIONS
181	Assessing the Origin of and Potential for International Spread of Chikungunya Virus from the Caribbean. PLOS Currents, $2014, 6, .$	1.4	64
182	Vectorial Capacity of Aedes aegypti: Effects of Temperature and Implications for Global Dengue Epidemic Potential. PLoS ONE, 2014, 9, e89783.	1.1	319
183	Impact of partial sleep deprivation on immune markers. Sleep Medicine, 2013, 14, 1031-1034.	0.8	50
184	Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database. Lancet Infectious Diseases, The, 2013, 13, 205-213.	4.6	69
185	Acute HIV infection at travel clinics – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 651-652.	4.6	O
186	Dengue in International Travelers: Quo Vadis?. Journal of Travel Medicine, 2013, 20, 341-343.	1.4	3
187	HIV-related travel restrictions: trends and country characteristics. Global Health Action, 2013, 6, 20472.	0.7	18
188	Theoretical impact of insecticide-impregnated school uniforms on dengue incidence in Thai children. Global Health Action, 2013, 6, 20473.	0.7	9
189	Exploring the origin and potential for spread of the 2013 dengue outbreak in Luanda, Angola. Global Health Action, 2013, 6, 21822.	0.7	35
190	Dengue Research Funded by the European Commission-Scientific Strategies of Three European Dengue Research Consortia. PLoS Neglected Tropical Diseases, 2013, 7, e2320.	1.3	29
191	Persistence of Th 1 /Tc 1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Human Vaccines and Immunotherapeutics, 2013, 9, 2317-2325.	1.4	48
192	GeoSentinel Surveillance of Illness in Returned Travelers, 2007–2011. Annals of Internal Medicine, 2013, 158, 456.	2.0	380
193	Travel-associated Illness Trends and Clusters, 2000–2010. Emerging Infectious Diseases, 2013, 19, 1049-1073.	2.0	95
194	Epidemiology of dengue: past, present and future prospects. Clinical Epidemiology, 2013, 5, 299.	1.5	655
195	Dengue Infections. , 2013, , 301-311.		2
196	Mass Gatherings. , 2013, , 357-359.		1
197	Haze and dengue: the unanswered questions. Annals of the Academy of Medicine, Singapore, 2013, 42, 687-8.	0.2	0
198	DengueTools: innovative tools and strategies for the surveillance and control of dengue. Global Health Action, 2012, 5, 17273.	0.7	98

#	Article	IF	CITATIONS
199	Comparing Statistical Models to Predict Dengue Fever Notifications. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-6.	0.7	33
200	Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years. Human Vaccines and Immunotherapeutics, 2012, 8, 1259-1271.	1.4	90
201	Meningococcal disease in travelers. Current Opinion in Infectious Diseases, 2012, 25, 507-517.	1.3	24
202	Dengue infections in travellers. Paediatrics and International Child Health, 2012, 32, 28-32.	0.3	79
203	Transient Immune Impairment After a Simulated Long-Haul Flight. Aviation, Space, and Environmental Medicine, 2012, 83, 418-423.	0.6	8
204	Meteorological factors and El Ni $\tilde{A}\pm o$ Southern Oscillation are independently associated with dengue infections. Epidemiology and Infection, 2012, 140, 1244-1251.	1.0	86
205	Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine, 2012, 30, 329-335.	1.7	22
206	Expatriates ill after travel: Results from the Geosentinel Surveillance Network. BMC Infectious Diseases, 2012, 12, 386.	1.3	43
207	The impact of insecticide-treated school uniforms on dengue infections in school-aged children: study protocol for a randomised controlled trial in Thailand. Trials, 2012, 13, 212.	0.7	18
208	Latitudinal Patterns of Travel Among Returned Travelers With Influenza: Results From the GeoSentinel Surveillance Network, 1997–2007. Journal of Travel Medicine, 2012, 19, 4-8.	1.4	18
209	The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease. Vaccine, 2011, 29, 3363-3371.	1.7	105
210	Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infectious Diseases, The, 2011, 11, 677-683.	4.6	162
211	The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infectious Diseases, The, 2011, 11, 622-632.	4.6	222
212	An exploratory study of treated-bed nets in Timor-Leste: patterns of intended and alternative usage. Malaria Journal, 2011, 10, 199.	0.8	36
213	Vaccination of travelers: how far have we come and where are we going?. Expert Review of Vaccines, 2011, 10, 1609-1620.	2.0	11
214	Patterns of Illness in Travelers Visiting Mexico and Central America: The GeoSentinel Experience. Clinical Infectious Diseases, 2011, 53, 523-531.	2.9	31
215	Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development. Current Infectious Disease Reports, 2010, 12, 157-164.	1.3	176
216	Meningococcal Disease in Travelers: A Rare But Devastating Disease. Journal of Travel Medicine, 2010, 17, 1-2.	1.4	14

#	Article	IF	CITATIONS
217	Cross-Reactive Antibodies to Pandemic (H1N1) 2009 Virus, Singapore. Emerging Infectious Diseases, 2010, 16, 874-876.	2.0	35
218	Vaccination against tetanus, diphtheria, pertussis and poliomyelitis in adult travellers. Travel Medicine and Infectious Disease, 2010, 8, 155-160.	1.5	29
219	Vaccine preventable diseases in returned international travelers: Results from the GeoSentinel Surveillance Network. Vaccine, 2010, 28, 7389-7395.	1.7	108
220	Threat of Dengue to Blood Safety in Dengue-Endemic Countries. Emerging Infectious Diseases, 2009, 15, 8-11.	2.0	126
221	Combination strategies for pandemic influenza response - a systematic review of mathematical modeling studies. BMC Medicine, 2009, 7, 76.	2.3	74
222	Yellow Fever Recommendations for Tourists to Kenya: A Flawed Risk Assessment. Journal of Travel Medicine, 2009, 16, 146.1-146.	1.4	4
223	Risk Estimates of Dengue in Travelers to Dengue Endemic Areas Using Mathematical Models. Journal of Travel Medicine, 2009, 16, 191-193.	1.4	34
224	Latent Tuberculosis Infection in Travelers: Is There a Role for Screening Using Interferonâ€Gamma Release Assays?. Journal of Travel Medicine, 2009, 16, 352-356.	1.4	3
225	Expert Opinion on Vaccination of Travelers Against Japanese Encephalitis. Journal of Travel Medicine, 2009, 16, 204-216.	1.4	56
226	Ross River Virus Disease in a Traveler to Australia. Journal of Travel Medicine, 2009, 16, 420-423.	1.4	7
227	A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. Journal of Infection, 2009, 59, 19-27.	1.7	116
228	Japanese encephalitis: is there a need for a novel vaccine?. Expert Review of Vaccines, 2009, 8, 969-972.	2.0	14
229	Meningococcal vaccines: a neglected topic in travel medicine?. Expert Review of Vaccines, 2009, 8, 1343-1350.	2.0	16
230	Meningococcal Disease in International Travel: Vaccine Strategies. Journal of Travel Medicine, 2008, 12, S22-S29.	1.4	8
231	<i>Fasciola hepatica</i> in a New Zealander Traveler. Journal of Travel Medicine, 2008, 15, 196-199.	1.4	18
232	Meningococcal disease: Risk for international travellers and vaccine strategies. Travel Medicine and Infectious Disease, 2008, 6, 182-186.	1.5	31
233	Yellow fever vaccines and international travelers. Expert Review of Vaccines, 2008, 7, 579-587.	2.0	23
234	Geographic Expansion of Dengue: The Impact of International Travel. Medical Clinics of North America, 2008, 92, 1377-1390.	1.1	299

#	Article	IF	Citations
235	Travel vaccines: current practice and future aspects. Expert Review of Vaccines, 2008, 7, 527-530.	2.0	2
236	Dengue vaccines for travelers. Expert Review of Vaccines, 2008, 7, 569-578.	2.0	19
237	Seasonality, Annual Trends, and Characteristics of Dengue among Ill Returned Travelers, 1997–2006. Emerging Infectious Diseases, 2008, 14, 1081-1088.	2.0	160
238	Importation of Poliomyelitis by Travelers. Emerging Infectious Diseases, 2008, 14, 351-352.	2.0	17
239	Title is missing!. , 2008, , 97.		1
240	The Revised International Health Regulations (2005): Impact on Yellow Fever Vaccination in Clinical Practice. American Journal of Tropical Medicine and Hygiene, 2008, 78, 359-360.	0.6	15
241	The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice. American Journal of Tropical Medicine and Hygiene, 2008, 78, 359-60.	0.6	4
242	Severe Dengue Virus Infection in Travelers. Journal of Infectious Diseases, 2007, 195, 1081-1083.	1.9	22
243	Meningococcal vaccine in travelers. Current Opinion in Infectious Diseases, 2007, 20, 454-460.	1.3	38
244	Fulminant hepatitis in dengue haemorrhagic fever. Journal of Clinical Virology, 2007, 38, 265-268.	1.6	69
245	As Travel Medicine Practitioner during the SARS Outbreak in Singapore. , 2007, , 313-319.		0
246	Knowledge, Attitude, and Practices With Regard to Adult Pertussis Vaccine Booster in Travelers. Journal of Travel Medicine, 2007, 14, 145-150.	1.4	13
247	The Revised International Health Regulations and Their Relevance to Travel Medicine. Journal of Travel Medicine, 2007, 14, 141-144.	1.4	28
248	Meningococcal Disease and the Hajj Pilgrimage. , 2007, , 171-176.		0
249	The severe acute respiratory syndrome: Impact on travel and tourism. Travel Medicine and Infectious Disease, 2006, 4, 53-60.	1.5	157
250	Distinguishing dengue fever from other infections on the basis of simple clinical and laboratory features: Application of logistic regression analysis. Journal of Clinical Virology, 2006, 35, 147-153.	1.6	110
251	Confronting the New Challenge in Travel Medicine: SARS. Journal of Travel Medicine, 2006, 10, 257-258.	1.4	21
252	In-flight transmission of Severe Acute Respiratory Syndrome (SARS): A Case Report. Journal of Travel Medicine, 2006, 10, 299-300.	1.4	34

#	Article	IF	CITATIONS
253	Meningococcal Carriage in Umra Pilgrims Returning from Saudi Arabia. Journal of Travel Medicine, 2006, 10, 147-149.	1.4	15
254	Global Impact of Severe Acute Respiratory Syndrome: Measures to Prevent Importation into Saudi Arabia. Journal of Travel Medicine, 2006, 11, 127-129.	1.4	7
255	Illness in Travelers Visiting Friends and Relatives: A Review of the GeoSentinel Surveillance Network. Clinical Infectious Diseases, 2006, 43, 1185-1193.	2.9	328
256	Tourism and SARS. , 2006, , 53-61.		12
257	Changes in Body Fat Measured by DEXA in Patients Taking Different Formulations of Stavudine. HIV Clinical Trials, 2005, 6, 337-343.	2.0	9
258	High risk of Mycobacterium tuberculosis infection during the Hajj pilgrimage. Tropical Medicine and International Health, 2005, 10, 336-339.	1.0	72
259	Asymptomatic SARS Coronavirus Infection among Healthcare Workers, Singapore. Emerging Infectious Diseases, 2005, 11, 1142-1145.	2.0	151
260	Dengue in Travelers. New England Journal of Medicine, 2005, 353, 924-932.	13.9	383
261	Serological evidence for the co-circulation of multiple dengue virus serotypes in Singapore. Epidemiology and Infection, 2005, 133, 667-671.	1.0	34
262	Risk of respiratory infections in health care workers: lessons on infection control emerge from the SARS outbreak. Southeast Asian Journal of Tropical Medicine and Public Health, 2005, 36, 481-8.	1.0	17
263	Use of Simple Laboratory Features to Distinguish the Early Stage of Severe Acute Respiratory Syndrome from Dengue Fever. Clinical Infectious Diseases, 2004, 39, 1818-1823.	2.9	49
264	Travel Health Knowledge, Attitudes and Practices among Australasian Travelers. Journal of Travel Medicine, 2004, 11, 9-15.	1.4	157
265	Seroepidemiology of dengue in the adult population of Singapore. Tropical Medicine and International Health, 2004, 9, 305-308.	1.0	68
266	Short communication: Low risk of transmission of severe acute respiratory syndrome on airplanes: the Singapore experience. Tropical Medicine and International Health, 2003, 8, 1035-1037.	1.0	69
267	W-135 Meningococcal Disease in a Traveler: A Case Report. Journal of Travel Medicine, 2003, 10, 59-60.	1.4	11
268	Meningococcal disease and travel. International Journal of Antimicrobial Agents, 2003, 21, 102-106.	1.1	44
269	W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience. International Journal of Antimicrobial Agents, 2003, 21, 112-115.	1.1	18
270	Hajjâ€Associated Outbreak Strain ofNeisseria meningitidisSerogroup W135: Estimates of the Attack Rate in a Defined Population and the Risk of Invasive Disease Developing in Carriers. Clinical Infectious Diseases, 2003, 36, 679-683.	2.9	105

#	Article	IF	CITATIONS
271	High Incidence of Pertussis among Hajj Pilgrims. Clinical Infectious Diseases, 2003, 37, 1270-1272.	2.9	51
272	Absence of Neisseria meningitidis W-135 Electrophoretic Type 37 during the Hajj, 2002. Emerging Infectious Diseases, 2003, 9, 734-737.	2.0	25
273	Persistence of W135 <i>Neisseria meningitidis</i> Carriage in Returning Hajj Pilgrims: Risk for Early and Late Transmission to Household Contacts. Emerging Infectious Diseases, 2003, 9, 123-126.	2.0	47
274	Experience of Severe Acute Respiratory Syndrome in Singapore: Importation of Cases, and Defense Strategies at the Airport. Journal of Travel Medicine, 2003, 10, 259-262.	1.4	57
275	Severe acute respiratory syndrome: Imported cases of severe acute respiratory syndrome to Singapore had impact on national epidemic. BMJ: British Medical Journal, 2003, 326, 1393-a-1394.	2.4	8
276	Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ: British Medical Journal, 2002, 325, 365-366.	2.4	67
277	Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet, The, 2002, 360, 644-645.	6.3	14
278	Crossover Vaccination with Quadrivalent Meningococcal Vaccine (against A/C/Y/W-135) Following Recent Application of Bivalent Meningococcal Vaccine (against A/C): Assessment of Safety and Side Effect Profile. Journal of Travel Medicine, 2002, 9, 20-23.	1.4	8
279	Comparison of Immunogenicity and Safety of a Virosome Influenza Vaccine with Those of a Subunit Influenza Vaccine in Pediatric Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2000, 44, 1163-1167.	1.4	58
280	Neurological Signs and Symptoms in Travelers. , 0, , 427-433.		0
281	Viral Hemorrhagic Fevers. , 0, , 107-118.		1